Advertisement
Advertisement

ORIC

ORIC logo

Oric Pharmaceuticals, Inc. Common Stock

10.26
USD
Sponsored
-0.50
-4.64%
Jan 30, 16:00 UTC -5
Closed
exchange

After-Market

10.59

+0.32
+3.16%

ORIC Earnings Reports

Positive Surprise Ratio

ORIC beat 12 of 23 last estimates.

52%

Next Report

Date of Next Report
Feb 16, 2026
Estimate for Q4 25 (Revenue/ EPS)
--
/
-$0.37
Implied change from Q3 25 (Revenue/ EPS)
--
/
+12.12%
Implied change from Q4 24 (Revenue/ EPS)
--
/
-27.45%

Oric Pharmaceuticals, Inc. Common Stock earnings per share and revenue

On Nov 13, 2025, ORIC reported earnings of -0.33 USD per share (EPS) for Q3 25, beating the estimate of -0.41 USD, resulting in a 20.14% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +0.49% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 17 analysts forecast an EPS of -0.37 USD, with revenue projected to reach -- USD, implying an increase of 12.12% EPS, and increase of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Nurix Therapeutics, Inc. Common stock
Report Date
Jan 28, 2026 For Q4 25
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.66%
logo
Regeneron Pharmaceuticals Inc
Report Date
Jan 30, 2026 For Q4 25
Estimate
$10.84
Actual
$11.44
Surprise
+5.52%
FAQ
For Q3 2025, Oric Pharmaceuticals, Inc. Common Stock reported EPS of -$0.33, beating estimates by 20.14%, and revenue of $0.00, 0% as expectations.
The stock price moved up 0.49%, changed from $12.19 before the earnings release to $12.25 the day after.
The next earning report is scheduled for Feb 16, 2026.
Based on 17 analysts, Oric Pharmaceuticals, Inc. Common Stock is expected to report EPS of -$0.37 and revenue of -- for Q4 2025.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement